To Combat Cancer Cell Lines, the Development, and Evaluation of Lycopene-Co-Loaded TAMOXIFEN Nanoparticles

Abstract

One common issue with chemotherapy-based cancer treatments is drug resistance. Plants that can fight cancer can effectively improve their secondary metabolites at the nanoscale. The chemical formula for lycopene is C₄₀H₅₆. This tetraterpene and beta-carotene, which is used as an anti-wrinkle ingredient in cosmetics, can inhibit the growth of cancer cells. The selective estrogen receptor modulator tamoxifen is used to treat estrogen receptor-positive breast cancer, lower the risk of invasive breast cancer after surgery, or lower the risk of breast cancer in women who are at high risk. Oil-in-oil (O/O) emulsion solvent evaporation techniques were used to create Lycopene and TAM-loaded Eudragit nanoparticles (LTENPs), which have been shown to increase bioavailability and exhibit a synergistic impact. For LTENPs, the zeta potential—a measurement of a nanoparticle's relative stability—was discovered to be -45.1 mV. Lycopene and TAM were found to have percentage encapsulation efficiency values of 72% and 75%, respectively. TEM indicates that the particles in the LTENPs range in size from 26 to 34 nm. The prolonged release and much greater antioxidant and anti-cancer properties of the LTENPs were in contrast to those of free Lycopene and TAM particles alone. The in vitro investigations demonstrated the combination's strong anticancer potential by showing that it dramatically suppressed the growth of MCF-7 cell lines when compared to Lycopene, TAM, and Eudragit alone.